- In October 2024, Illumina, Inc. launched its MiSeq i100 Series of sequencing systems, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories. This innovation will help Illumina strengthen its leadership in the NGS market by providing more efficient, user-friendly solutions for a wider range of customers
- In September 2024, at the Illumina India Genomics Summit, Illumina unveiled the creation of a Global Capability Center in Bengaluru, India, aimed at expanding its technology workforce to better serve its global customer base. This expansion will enhance the company’s innovation and support capabilities worldwide
- In September 2024, MGI Tech Co., Ltd. has formed a strategic partnership with Dasa to enhance Brazilian patients' access to next-generation genomics and drive significant progress in Brazil's healthcare sector. This collaboration will strengthen MGI Tech's presence in the Brazilian market and accelerate the adoption of advanced genomic technologies
- In August 2024, Ambry Genetics introduced the ExomeReveal test, a multiomic exome sequencing tool designed to enhance rare disease detection beyond traditional DNA-based methods. By incorporating its expertise in RNA analysis from hereditary cancer testing, the ExomeReveal test improves diagnostic yield for rare diseases. This advancement will help Ambry Genetics expand its diagnostic capabilities and strengthen its position in the rare disease market
- In April 2024, GeneDx has announced a strategic partnership with Komodo Health to expand access to its de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, which includes data from over 500,000 exomes. This collaboration will provide biopharma companies with valuable genetic insights, enhancing drug pipeline development and clinical trial enrollment. The partnership will bolster GeneDx's position in the biopharma sector by facilitating faster drug development and broader industry collaboration
